Skip to main content
. 2016 Nov 3;7(47):76374–76389. doi: 10.18632/oncotarget.13062

Figure 3. Differential response to cisplatin treatment in PDXs and associated mutational status and gene expression.

Figure 3

A. Cisplatin treatment (5 mg/kg and 10 mg/kg) had a differential effect on BLCAb001 and BLCAb002 in vivo growth. B. Mutational status of cisplatin resistance associated genes in BLCAb001 and BLCAb002. C. RT-PCR and Western blot analysis of SLC7A11 (xCT), a cisplatin resistance associated gene in BLCAb001 and BLCAb002 PDXs. D. Immunohistochemical evaluation of xCT in BLCAb001 and BLCAb002. E. Percent tumors with high and low xCT expression. Immunoscore determined as high (80-100% cells positive) and low (2-20% cells positive) [35]. F. TCGA data analysis of cBioportal showing the poor survival of patients with alteration (upregulation) of SLC7A11 (xCT). Logrank test p-value 0.0312. G. SLC7A11 gene methylation in human bladder cancer patients primary tumors (n = 22) and the matched non-tumor tissues (n = 106). This graph shows the presence of DNA hypomethylation within the SLC7A11 locus. Each data point represents the average methylation of 2 CG sites most significantly hypomethylated in tumors when compared to normal bladder tissues.